(1) 甾体激素药物研究及产业化
(2) 抗肿瘤药物研究
(3) 代谢性疾病治疗药物研究

1. 主持国家自然科学基金面上项目（基于RCT途径构建新型PPARγ/LXRα双靶点调血脂药物的研究，81874286）.
2. 主持国家自然科学基金面上项目（基于ERα/VEGFR双靶点抗乳腺癌药物设计、生物活性评价及作用机制研究，81373279）.
3. 主持科技部“重大新药创制”科技重大专项（化药1.1类调血脂候选新药Oleoyl Formononetin的研究，2012ZX09103101-041）.
4. 主持江苏省科技支撑计划-社会发展项目（ERα/VEGFR双靶点抗乳腺癌药物研究，BE2012745）.
5. 主持江苏省“六大人才高峰”项目（基于CETP的调血脂药物分子发现及活性研究，2013-YY003）.
6. 主持南京市领军型科技创业人才计划项目：创新药物及医药中间体研发及产业化.
7. 主持江苏省国际合作项目（SERM化合物设计、合成及生物活性，BZ2008058）.
8. 主持国家发改委西部高技术产业化示范工程子项：蕃蔴二烯物合成甾体激素药物的研究.
9. 参加科技部“重大新药创制”科技重大专项（抗乳腺癌候选药物，2012ZX09103101-048）.
10. 与多家甾体激素制药企业合作，主持多项新药研究项目，作为项目负责人获得新药证书三本，负责开发的多个原料药品种投放生产。
​

1.Shuangshuang Xiong, Xin Wang, Meiqi Zhu, Ke Song, Yefan Li, Jiaqi Yang, Xinyan Liu , Mofei Liu, Haijuan Dong, Mingqi Chen, Deying Chen, Hua Xiang*, Guoshun Luo*. Structural optimization of tetrahydroisoquinoline-hydroxamate hybrids as potent dual ERα degraders and HDAC inhibitors. Bioorg Chem, 2023, 134, 106459. doi: 10.1016/j.bioorg.2023.106459. Mar 10, 2023. (SCI IF: 5.275)
2.Maoxu Xiao, Meiqi Zhu, Shuangjie Wu, Luyu Ma, Lin Qi, Si Ha, Shuangshuang Xiong, Mingqi Chen, Deying Chen, Guoshun Luo*, Hua Xiang*. Novel 6-amino-1,3,5-triazine derivatives as potent BTK inhibitors: structure-activity relationship (SAR) analysis and preliminary mechanism investigation. Bioorg Chem, 2023, 130, 106263. doi: 10.1016/j.bioorg.2022.106263. Nov 8, 2022. (SCI IF: 5.275)
3.Si Ha, Guoshun Luo*, Hua Xiang*. A Comprehensive Overview of Small-Molecule Androgen Receptor Degraders: Recent Progress and Future Perspectives. J Med Chem, 2023, https://doi.org/10.1021/acs.jmedchem.2c01487. Sep 22,2022. (SCI IF: 7.300)
4.Guoshun Luo*, Xinyu Li, Xin Lin, Xiang Lu, Zhenbang Li, Hua Xiang*. Novel 11β-substituted estradiol conjugates: Transition from ERα agonists to effective PROTAC degraders. J Steroid Biochem Mol Biol, 2022, 223, 106154. (SCI IF: 5.011)
5.Guoshun Luo, Xin Lin, Antonio Vega-Medina, Maoxu Xiao, Guolong Li, Hanlin Wei, Carlos A. Velázquez-Martínez*, Hua Xiang*. Targeting of the FOXM1 oncoprotein by E3 ligase-assisted degradation. J Med Chem, 2021, 64, 17098−17114. https://doi.org/10.1021/acs.jmedchem.1c01069. Nov 23, 2021. (SCI IF: 7.446)
6.Guoshun Luo, Xin Lin, Shengnan Ren, Shuangjie Wu, Xin Wang, Luyu Ma, Hua Xiang*. Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer. Eur J Med Chem, 2021, 226: 113870. https://doi.org/10.1016/j.ejmech.2021.113870. Sep 25,2021. (SCI IF:6.409)
7.Chenfeng Bai, Shengnan Ren, Shuangjie Wu, Meiqi Zhu, Guoshun Luo, Hua Xiang*. Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer. Eur J Med Chem, 2021, 221: 113543. https://doi.org/10.1016/j.ejmech.2021.113543. May 14, 2021. (SCI IF:6.409)
8.Xiang Lu, Yu Teng, Xin Lin, Maoxu Xiao, Chenna Liu, Xinglong Chi, Yulan Zhang, Guoshun Luo*, Hua Xiang*. Discovery of novel 2H-chromene-3-carbonyl derivatives as selective estrogen receptor degraders (SERDs): Design, synthesis and biological evaluation. Bioorg Chem, 2021, 109, 104714. doi.org/10.1016/j.bioorg.2021.104714. Feb 9, 2021. (SCI IF:4.819)
9.Guoshun Luo, Xin Lin, Zhenbang Li, Maoxu Xiao, Xinyu Li, Dayong Zhang*, Hua Xiang*. Structure-guided modification of isoxazole-type FXR agonists: Identification of a potent and orally bioavailable FXR modulator. Eur J Med Chem, 2021, 209, 112910. https://doi.org/10.1016/j.ejmech.2020.112910. Oct. 7, 2020. (SCI IF:6.409)
10.Guoshun Luo, Zhenbang Li, Xin Lin, Xinyu Li, Yu Chen, Kun Xi, Maoxu Xiao, Hanlin Wei, Lizhe Zhu*, Hua Xiang*. Discovery of an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo. Acta Pharm Sin B 2021; 11(5):1300-1314. https://doi.org/10.1016/j.apsb.2020.11.001. Oct. 30, 2020. (SCI IF:10.746)

向华 教授
骆国顺 特聘副研究员
博士研究生
肖茂旭（2021级） 陶文祥（2022级）
硕士研究生
马露雨（2020级）齐麟（2020级）朱美旗（2020级）
哈斯（2021级）熊爽爽（2021级）
祝佳程（2022级）陈巍（2022级）杨铭（2022级）